ZA200803350B - Method of acting upon organism by targeted delivery of biologically active substances into mitochondria, pharmaceutical composition for carrying out said method, and compound used for the purpose - Google Patents
Method of acting upon organism by targeted delivery of biologically active substances into mitochondria, pharmaceutical composition for carrying out said method, and compound used for the purposeInfo
- Publication number
- ZA200803350B ZA200803350B ZA200803350A ZA200803350A ZA200803350B ZA 200803350 B ZA200803350 B ZA 200803350B ZA 200803350 A ZA200803350 A ZA 200803350A ZA 200803350 A ZA200803350 A ZA 200803350A ZA 200803350 B ZA200803350 B ZA 200803350B
- Authority
- ZA
- South Africa
- Prior art keywords
- mitochondria
- organism
- acting
- carrying
- pharmaceutical composition
- Prior art date
Links
- 239000013543 active substance Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 210000003470 mitochondria Anatomy 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/54—Quaternary phosphonium compounds
- C07F9/5442—Aromatic phosphonium compounds (P-C aromatic linkage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/54—Quaternary phosphonium compounds
- C07F9/5456—Arylalkanephosphonium compounds
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B11/00—Diaryl- or thriarylmethane dyes
- C09B11/04—Diaryl- or thriarylmethane dyes derived from triarylmethanes, i.e. central C-atom is substituted by amino, cyano, alkyl
- C09B11/10—Amino derivatives of triarylmethanes
- C09B11/24—Phthaleins containing amino groups ; Phthalanes; Fluoranes; Phthalides; Rhodamine dyes; Phthaleins having heterocyclic aryl rings; Lactone or lactame forms of triarylmethane dyes
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B69/00—Dyes not provided for by a single group of this subclass
- C09B69/001—Dyes containing an onium group attached to the dye skeleton via a bridge
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2005132217/15A RU2318500C2 (ru) | 2005-10-18 | 2005-10-18 | Способ воздействия на организм путем адресной доставки биологически активных веществ в митохондрии, фармацевтическая композиция для его осуществления и соединение, применяемое для этой цели |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200803350B true ZA200803350B (en) | 2009-02-25 |
Family
ID=37962744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200803350A ZA200803350B (en) | 2005-10-18 | 2008-04-15 | Method of acting upon organism by targeted delivery of biologically active substances into mitochondria, pharmaceutical composition for carrying out said method, and compound used for the purpose |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9328130B2 (pt) |
| EP (1) | EP1937277A1 (pt) |
| JP (1) | JP2009511626A (pt) |
| KR (1) | KR20080059228A (pt) |
| CN (1) | CN101300014A (pt) |
| AU (1) | AU2006302751A1 (pt) |
| BR (1) | BRPI0617417A2 (pt) |
| CA (1) | CA2626305A1 (pt) |
| IL (1) | IL190951A0 (pt) |
| MX (1) | MX2008004939A (pt) |
| RU (1) | RU2318500C2 (pt) |
| WO (1) | WO2007046729A1 (pt) |
| ZA (1) | ZA200803350B (pt) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ575904A (en) * | 2006-09-28 | 2011-11-25 | Univ Otago | Triphenylphosphonium thionitrite nitric oxide donors |
| US9045505B2 (en) * | 2006-09-28 | 2015-06-02 | University Of Otago | Nitric oxide donors |
| US8557733B2 (en) | 2006-10-20 | 2013-10-15 | Mitotech S.A. | Composition for regenerating and stimulating growth of plants and for adapting plants to different stress factors |
| EP2119436A4 (en) * | 2006-10-20 | 2010-03-03 | Ltd Liability Company Mitotech | PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF EYE DISEASES |
| US8349902B2 (en) | 2007-01-29 | 2013-01-08 | Mitotech Sa | Pharmaceutical compositions useful for preventing and treating oncological diseases |
| WO2008094061A1 (fr) | 2007-01-29 | 2008-08-07 | Limited Liability Company 'mitotechnology' | Compositions pharmaceutiques et cosmétiques servant à accélérer le processus de cicatrisation de plaies et autres lésions superficielles |
| US9439916B2 (en) | 2007-04-11 | 2016-09-13 | Mitotech Sa | Composition for decelerating the aging in the organism and for extending the life time thereof and the use of said composition |
| US8518915B2 (en) * | 2007-06-29 | 2013-08-27 | Mitotech Sa | Use of mitochondrially-addressed compounds for preventing and treating cardiovascular diseases |
| US8598145B2 (en) | 2008-03-14 | 2013-12-03 | Stephen John Ralph | Mitochondrially delivered anti-cancer compounds |
| SG10201608068SA (en) * | 2008-04-01 | 2016-11-29 | Antipodean Pharmaceuticals Inc | Compositions And Methods For Skin Care |
| WO2010045220A1 (en) | 2008-10-14 | 2010-04-22 | Edison Pharmaceuticals, Inc. | Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells |
| WO2010056145A1 (ru) * | 2008-11-12 | 2010-05-20 | Общество С Ограниченной Ответственностью "Митотехнология" | Способ умеренного повышения протонной проводимости биологических мембран при помощи митохондриально- адресованных делокализованных катионов |
| EP2441453B1 (en) * | 2009-06-10 | 2014-11-26 | Mitotech SA | Pharmaceutical composition for use in medical and veterinary ophthalmology |
| KR20120125980A (ko) * | 2009-11-13 | 2012-11-19 | 리미티드 라이어빌러티 컴퍼니 미토테크 | 미토콘드리아 표적화된 항산화제에 기초한 약학적 물질 |
| RU2527519C2 (ru) * | 2010-06-24 | 2014-09-10 | Общество С Ограниченной Ответственностью "Митотех" | Мягкие катионные митохондриальные разобщители |
| WO2011162633A1 (ru) * | 2010-06-24 | 2011-12-29 | Общество С Ограниченной Ответственностью "Mиtotex" | Мягкие катионные митохондриальные разобщители |
| WO2012009171A2 (en) * | 2010-07-15 | 2012-01-19 | The Schepens Eye Research Institute, Inc. | Compositions and methods of treatment of corneal endothelium disorders |
| EA201300215A1 (ru) * | 2010-08-06 | 2013-07-30 | Эдисон Фармасьютикалз, Инк. | Лечение митохондриальных болезней нафтохинонами |
| WO2012110435A1 (en) * | 2011-02-14 | 2012-08-23 | Basf Se | Bio process additives |
| JO3733B1 (ar) * | 2011-04-05 | 2021-01-31 | Bayer Ip Gmbh | استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة |
| EA031399B1 (ru) | 2011-06-03 | 2018-12-28 | Общество С Ограниченной Ответственностью "Митотех" | Изготовление и использование пероральных фармацевтических композиций на основе митохондриально-адресованных антиоксидантов |
| AU2012289698B2 (en) * | 2011-08-04 | 2017-04-20 | Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture And Agri-Food | Organelle targeting nanocarriers |
| WO2013044058A1 (en) | 2011-09-22 | 2013-03-28 | Mitotech S.A. | Mitochondria-targeted antioxidants for treatment of age-related brain disorders |
| GB201117095D0 (en) * | 2011-09-30 | 2011-11-16 | Univ Exeter The | Novel hydrogen sulfide releasing compounds |
| EP2671574A1 (en) | 2012-06-04 | 2013-12-11 | VitaK B.V. | Use of vitamin K to decrease allograft failure and patient mortality after organ transplantation |
| WO2014039917A1 (en) | 2012-09-07 | 2014-03-13 | Edison Pharmaceuticals, Inc. | Benzoquinone derivatives for treating oxidative stress disorders |
| KR101490580B1 (ko) * | 2013-02-15 | 2015-02-05 | 경북대학교 산학협력단 | 미토콘드리아 타겟팅용 펩타이드 |
| WO2015063553A2 (en) * | 2013-04-11 | 2015-05-07 | Mitotech S.A. | Mitochondrially-targeted timoquinones and toluquinones |
| WO2015162494A2 (en) * | 2014-02-25 | 2015-10-29 | Mitotech, S.A. | Cosmetic compositions of mitochonrially targeted antioxidants |
| WO2015185918A1 (en) | 2014-06-02 | 2015-12-10 | University Of Exeter | Combinations of a photosensitizer with a hydrogen sulfide donor, thioredoxin inhibitor or nitroxide for use in photodynamic therapy |
| US20180185276A1 (en) * | 2015-03-26 | 2018-07-05 | Mitotech S.A. | Contact lenses carrying mitochonrially-targeted antioxidants |
| TW201706312A (zh) * | 2015-05-20 | 2017-02-16 | 免疫功坊股份有限公司 | 用以治療疾病的分子構建體 |
| RU2637279C2 (ru) * | 2015-12-25 | 2017-12-01 | Сергей Петрович Кречетов | Способ фотодинамической терапии |
| CN105506053B (zh) * | 2015-12-30 | 2018-06-19 | 北京农学院 | 一种草莓果肉细胞凋亡的检测方法 |
| EP3330274A1 (en) * | 2016-12-01 | 2018-06-06 | Springtide Ventures s.r.o. | Compounds for treatment of senescence-related disorders |
| WO2019002936A2 (en) | 2017-06-26 | 2019-01-03 | Mitotech S.A. | SET OF COMPOUNDS TARGETING MITOCHONDRIA |
| MX2020005311A (es) * | 2017-11-24 | 2020-08-17 | Lunella Biotech Inc | Compuestos de derivados de trifenilfosfonio para erradicar celulas madre cancerosas. |
| US20210121570A1 (en) * | 2018-06-21 | 2021-04-29 | Georgios VOUGIOUKALAKIS | Method |
| CN109232216A (zh) * | 2018-11-11 | 2019-01-18 | 苏州怡彼得生物技术有限公司 | 一种线粒体靶向抗氧化剂skq1二季膦盐衍生物的合成方法 |
| CN109232219A (zh) * | 2018-11-11 | 2019-01-18 | 苏州怡彼得生物技术有限公司 | 一种线粒体靶向抗氧化剂skq1中间体2,3-二甲基-对苯醌的合成方法 |
| CN113939342A (zh) * | 2019-01-25 | 2022-01-14 | Mti生物技术公司 | 连接三苯基膦鎓的水杨胺衍生物 |
| CN110872220B (zh) * | 2019-12-19 | 2022-04-26 | 苏州怡彼得生物技术有限公司 | 一种靶向抗氧化剂skq1中间体2,3-二溴-5,6-二甲基-对苯醌的合成方法 |
| CN111117379A (zh) * | 2020-01-13 | 2020-05-08 | 广州铭汇建设工程有限公司 | 管道防锈涂料 |
| EP4210695A1 (en) | 2020-09-09 | 2023-07-19 | Social Profit Network | Methods and compositions for delivery of biotin to mitochondria |
| CN112341493B (zh) * | 2020-10-21 | 2023-08-15 | 重庆医药高等专科学校附属第一医院(重庆市职业病防治院重庆市第六人民医院重庆市中毒控制中心) | 一种基于三苯基膦修饰的线粒体靶向褪黑素及其制备方法和应用 |
| CN113480528B (zh) * | 2021-08-16 | 2023-05-30 | 四川大学华西医院 | 一种专一靶向线粒体且高效产生单线态氧的咪唑类光敏剂及其制备方法 |
| WO2023194946A1 (en) * | 2022-04-06 | 2023-10-12 | Kashiv Biosciences, Llc | An improved cell culture process for production of protein |
| US12077553B1 (en) * | 2023-11-09 | 2024-09-03 | Mitotech Ltd | Crystalline form of antioxidant compound |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE296305T1 (de) * | 1997-11-25 | 2005-06-15 | Antipodean Biotechnology Ltd | Antioxidantien mit spezifischer wirkung auf mitochondrien |
| US6331532B1 (en) * | 1998-11-25 | 2001-12-18 | University Of Otago | Mitochondrially targeted antioxidants |
| WO2005019233A1 (en) * | 2003-08-22 | 2005-03-03 | Antipodean Pharmaceuticals, Inc. | Mitoquinone derivatives used as mitochondrially targeted antioxidants |
| CA2354743A1 (en) * | 2001-08-07 | 2003-02-07 | University Of Otago | Mitochondrially targeted antioxidants |
| US6984636B2 (en) * | 2002-08-12 | 2006-01-10 | Medical Research Council | Mitochondrially targeted antioxidants |
-
2005
- 2005-10-18 RU RU2005132217/15A patent/RU2318500C2/ru active IP Right Revival
-
2006
- 2006-07-24 MX MX2008004939A patent/MX2008004939A/es not_active Application Discontinuation
- 2006-07-24 JP JP2008536535A patent/JP2009511626A/ja active Pending
- 2006-07-24 CA CA002626305A patent/CA2626305A1/en not_active Abandoned
- 2006-07-24 WO PCT/RU2006/000394 patent/WO2007046729A1/en active Application Filing
- 2006-07-24 CN CNA2006800388754A patent/CN101300014A/zh active Pending
- 2006-07-24 EP EP06784084A patent/EP1937277A1/en active Pending
- 2006-07-24 KR KR1020087009246A patent/KR20080059228A/ko not_active Application Discontinuation
- 2006-07-24 AU AU2006302751A patent/AU2006302751A1/en not_active Abandoned
- 2006-07-24 BR BRPI0617417-5A patent/BRPI0617417A2/pt not_active IP Right Cessation
-
2008
- 2008-01-10 US US11/972,437 patent/US9328130B2/en active Active
- 2008-04-15 ZA ZA200803350A patent/ZA200803350B/xx unknown
- 2008-04-17 IL IL190951A patent/IL190951A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN101300014A (zh) | 2008-11-05 |
| EP1937277A1 (en) | 2008-07-02 |
| RU2005132217A (ru) | 2007-04-27 |
| AU2006302751A1 (en) | 2007-04-26 |
| CA2626305A1 (en) | 2007-04-26 |
| JP2009511626A (ja) | 2009-03-19 |
| US9328130B2 (en) | 2016-05-03 |
| RU2318500C2 (ru) | 2008-03-10 |
| US20080176929A1 (en) | 2008-07-24 |
| IL190951A0 (en) | 2009-09-22 |
| MX2008004939A (es) | 2008-09-12 |
| WO2007046729A1 (en) | 2007-04-26 |
| KR20080059228A (ko) | 2008-06-26 |
| BRPI0617417A2 (pt) | 2011-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200803350B (en) | Method of acting upon organism by targeted delivery of biologically active substances into mitochondria, pharmaceutical composition for carrying out said method, and compound used for the purpose | |
| BRPI0607198A2 (pt) | composição, uso da composição método de tratamento doenças, e, embalagem farmacêutica | |
| IL225207A (en) | A derivative of multi-ring carbamoylpyridone, its pharmaceutical composition, its use and its preparation | |
| ZA200608029B (en) | Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs | |
| ZA200711040B (en) | Method and composition for transdermal drug delivery | |
| IL185390A (en) | A solid dosage form | |
| WO2007070052A3 (en) | Pharmaceutical compositions and methods for treating or preventing oxalate-related disease | |
| EP1971288A4 (en) | MICRONIZED DEVICE FOR DELIVERY OF BIOLOGICALLY ACTIVE MOLECULES AND METHOD OF USE | |
| IL185517A0 (en) | Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer | |
| EP2078731A4 (en) | PHARMACEUTICAL COMPOSITION COMPRISING ANTI-HB-EGF ANTIBODY AS ACTIVE INGREDIENT | |
| CL2007003444A1 (es) | Compuestos derivados de pirrolo[3,2-c]piridina; composicion farmaceutica; y uso en el tratamiento de un trastorno hiperproliferativo o una enfermedad inflamatoria. | |
| CL2007001630A1 (es) | Compuestos derivados de pirrolidinamida; composicion farmaceutica; y uso para el tratamiento de la hepatitis c. | |
| BRPI0807285A2 (pt) | "composição, método para preparar composição farmacêutica, forma unitária de dosagem, método para admnistrar um agente biologicamente ativo a um animal necessitando o agente, método para aumentar a biodisponibilidade de um agente biologicamente ativo, método para preparar uma composição e composto" | |
| CL2007002619A1 (es) | Compuestos derivados de 3-aza-biciclo[4.1.0]heptano; composicion farmaceutica; y uso en el tratamiento de la depresion. | |
| CL2007002376A1 (es) | Compuestos derivados de pirrol sustituido; proceso de preparacion; composicion farmaceutica; y uso en enfermedades bacterianas. | |
| CL2008002353A1 (es) | Compuestos derivados de 7h-indolo[2,1-a][2]benzazepina; composicion farmaceutica; y uso en el tratamiento de la hepatitis c. | |
| DE502007005902D1 (de) | -methyl-19-nor-20- spirox-4-en-3-one), sowie diese enthaltende pharmazeutische präparate | |
| CL2007003038A1 (es) | Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos. | |
| CL2007003672A1 (es) | Compuestos derivados de heteroaril-pirrolidinil-cetona y heteroaril-piperidinil-cetona; composicion farmaceutica; y uso en el tratamiento de la depresion y ansiedad. | |
| BRPI0720323A2 (pt) | composto, método de tratamento, composição farmacêutica e uso do composto | |
| ZA200700397B (en) | Novel benzamidine derivatives, process for the preparation thereof and pharmaceutical composition comprising the same | |
| EP1896038A4 (en) | METHOD AND COMPOSITION FOR THE TRANSDERMAL DISTRIBUTION OF MEDICINAL PRODUCTS | |
| CL2007001542A1 (es) | Compuestos derivados de aminotiazoles, composicion farmaceutica; y uso para el tratamiento de infecciones bacterianas. | |
| CL2007003693A1 (es) | Compuestos derivados de pirido [3,2-b] [1,4] tiazina; composicion farmaceutica que contiene dichos compuestos; y su uso en el tratamiento de infecciones bacterianas. | |
| ATE462408T1 (de) | Pharmazeutische zusammensetzungen, enthaltend valatograst, und verfahren zu deren herstellung |